[go: up one dir, main page]

CO5560543A2 - Derivados de indeno [1,2-c] isoquinolina y metodos para usar los mismos - Google Patents

Derivados de indeno [1,2-c] isoquinolina y metodos para usar los mismos

Info

Publication number
CO5560543A2
CO5560543A2 CO04016685A CO04016685A CO5560543A2 CO 5560543 A2 CO5560543 A2 CO 5560543A2 CO 04016685 A CO04016685 A CO 04016685A CO 04016685 A CO04016685 A CO 04016685A CO 5560543 A2 CO5560543 A2 CO 5560543A2
Authority
CO
Colombia
Prior art keywords
methods
isoquinoline
same
indeno
derivatives
Prior art date
Application number
CO04016685A
Other languages
English (en)
Inventor
Prakash G Jagtap
Erkan Baloglu
Duzer John H Van
Csaba Szabo
Andrew L Salzman
Original Assignee
Inotek Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inotek Pharmaceuticals Corp filed Critical Inotek Pharmaceuticals Corp
Publication of CO5560543A2 publication Critical patent/CO5560543A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4743—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)

Abstract

1.- Un compuesto de la fórmula y sales farmacéuticamente aceptables e hidratos del mismo,Donde:R5 es NH O S;R6 es -H O C1-C4 alquil;X es -C(O)-, -CH2, -CH(halo)-, -CH(OH) (CH2)n-, CH(OH)-arileno-, -O-, -NH-, -S- o -CH(NR11R12)-, donde n es un entero de 0-5;R11 y R12 son independientemente -hidrogeno o -C1-C9 alquil, o N, R11 y R12 tomados juntos forman una amina heterocíclica;R1, R2, R3, R4, R7, R8, R9 y R10 son independientemente -hidrógeno, -halo, -hidroxy, -O-(C1-C5 alquil), -C1-C10 alquil, -haloalquil, -C2C10 alquenil, -C3-C8 carbociclo, -aril, -NH2, -alquilamino, -C(O)OH, -C(O)O(C1-C5 alquil), OC(O)(C1-C5 alquil), NO2 o -A-B;donde A es -SO2-, -SO2NH-, -NHCO-, -NHCONH-, -O-, CO-, -OC(O)-, -C(O)O-, -CONH-, CON(C1-C4 alquil)-, NH-, -CH2-, -S- O -C(S)-;B es -C1-C10 alquil, -C2-C10 alquenil, -heterociclo, -C3-C8 carbociclo, -aril, -NZ1Z2, -alquilamino, aminodialquil, -alquilheterociclo, -arilamido, C(O)OH, -C(O)O-(C1-C5 alquil) O -C(O)O-fenil, donde ninguno de los cuales están no-sustituidos o sustituidos con uno o mas de -O-(C1-C5 alquil), halo, -haloalquil, -alcanol, -alquilamino, -hidroxi, -NO2, -NH2, -aminoalquil, -aminodialquil, -amina heterocíclica, -C1-C10 alquil, -C2-C10 alquenil, -C2-C10 alquinil, -aril, -benzil, -alquilamido, alquilcarboxi, -C1-C5 alquileno-C(O)O-C1-C5 alquil o grupos -C1-C5 alquileno-OC(O)-C1-C5 alquil; y Z1 y Z2 son independientemente -H o -C1-C10 alquil, los cuales están no-sustituidos o sustituidos con uno o mas de -halo, -OH o -N(Z3) (Z4), donde Z3 y Z4 son independientemente, -H o -C1-C5 alquil, donde están no-sustituidos o sustituidos con uno o mas de -halo, -hidroxi o -NH2; O N, Z3 y Z4 tomados juntos forman una amina heterocíclica sustituida o no sustituida, o N, Z1 y Z2 tomados juntos forman una amina heterocíclica.
CO04016685A 2001-08-31 2004-02-25 Derivados de indeno [1,2-c] isoquinolina y metodos para usar los mismos CO5560543A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/944,524 US20030096833A1 (en) 2001-08-31 2001-08-31 Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
CO5560543A2 true CO5560543A2 (es) 2005-09-30

Family

ID=25481570

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04016685A CO5560543A2 (es) 2001-08-31 2004-02-25 Derivados de indeno [1,2-c] isoquinolina y metodos para usar los mismos

Country Status (20)

Country Link
US (3) US20030096833A1 (es)
EP (2) EP2174659A1 (es)
JP (1) JP2005502681A (es)
KR (1) KR100922825B1 (es)
CN (2) CN100503574C (es)
AT (1) ATE465733T1 (es)
AU (1) AU2002329920B2 (es)
BR (1) BR0212225A (es)
CA (1) CA2457534A1 (es)
CO (1) CO5560543A2 (es)
DE (1) DE60236170D1 (es)
EC (1) ECSP044997A (es)
ES (1) ES2345436T3 (es)
IL (1) IL160437A0 (es)
MX (1) MXPA04001887A (es)
NO (1) NO20040845L (es)
NZ (1) NZ531218A (es)
RU (1) RU2300523C2 (es)
WO (1) WO2003020700A2 (es)
ZA (1) ZA200401376B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513450A (en) * 1999-02-12 2004-03-26 Glaxo Group Ltd Phosphoramidate, and mono-, di-, and tri-phosphate esters of (1R,cis)-4-(6-amino-9H-purin-9-yl)-2-cyclopentene- 1-methanol useful as antiviral agents
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
AU2004258801A1 (en) * 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
CA2525099A1 (en) * 2003-05-12 2004-11-25 Purdue Research Foundation Cytotoxic indeno and isoindoloisoquinolones
US20050261288A1 (en) * 2004-02-26 2005-11-24 Prakash Jagtap Tetracyclic lactam derivatives and uses thereof
US20050228007A1 (en) * 2004-02-26 2005-10-13 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
AP2006003791A0 (en) 2004-05-17 2006-10-31 Tibotec Pharm Ltd 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
JP2008503466A (ja) * 2004-06-16 2008-02-07 イノテック ファーマシューティカルズ コーポレイション 勃起不全または尿失禁を治療または予防する方法
MX2007010333A (es) * 2005-02-25 2007-11-06 Inotek Pharmaceuticals Corp Compuestos amino y carboxamido tetrac??clicos y m??todos para utilizar los mismos.
EP1850848A4 (en) * 2005-02-25 2008-02-20 Inotek Pharmaceuticals Corp SULFONAMIDE TETRACYCLIC COMPOUNDS AND METHODS OF USING THE SAME
AU2006219022A1 (en) * 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Isoqunoline Compounds and methods of use thereof
CA2620052A1 (en) * 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
US9399660B2 (en) 2005-11-14 2016-07-26 Purdue Research Foundation N-substituted indenoisoquinolines and syntheses thereof
WO2007059008A2 (en) 2005-11-14 2007-05-24 Purdue Research Foundation N-substituted indenoisoquinolines and syntheses thereof
WO2008106619A2 (en) * 2007-02-28 2008-09-04 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof
EP2528440A4 (en) 2010-01-27 2013-08-07 Purdue Research Foundation SUBSTITUTED NORINDEN ISOCHINOLINE, SYNTHESIS THEREOF AND METHOD OF USE THEREOF
JP2013526514A (ja) 2010-05-10 2013-06-24 ラディカル・セラピューティックス・インコーポレイテッド リポ酸およびニトロキシド誘導体およびその使用
US9073920B2 (en) 2010-08-17 2015-07-07 Purdue Research Foundation Substituted dibenzonaphthyridines, pharmaceutical uses thereof and processes therfor
US9682990B2 (en) 2011-05-25 2017-06-20 Purdue Research Foundation Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors
WO2012162513A2 (en) * 2011-05-25 2012-11-29 Purdue Research Foundation Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US8912213B2 (en) 2012-04-13 2014-12-16 Purdue Research Foundation Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (TDP1)- topoisomerase I (TOP1) inhibitors
US8686146B2 (en) 2012-07-13 2014-04-01 Purdue Research Foundation Azaindenoisoquinoline topoisomerase I inhibitors
US9034870B2 (en) 2012-07-13 2015-05-19 Purdue Research Foundation Azaindenoisoquinoline topoisomerase I inhibitors
CN105175333A (zh) * 2014-06-10 2015-12-23 中国人民解放军第二军医大学 5H-茚并[1,2-c]喹啉-6,11-二酮类化合物及其制备方法和用途
DK3325623T6 (da) 2015-07-23 2021-03-15 Inst Curie Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2017136616A1 (en) * 2016-02-04 2017-08-10 Purdue Research Foundation Prodrugs of anticancer agents indotecan and indimitecan
US10759795B2 (en) 2016-03-15 2020-09-01 Purdue Research Foundation Aza-A-ring indenoisoquinoline topoisomerase I poisons
JP7182548B2 (ja) 2016-12-22 2022-12-02 パードゥ リサーチ ファウンデーション アザインデノイソキノリン化合物およびその使用
AU2019235337A1 (en) 2018-03-13 2020-08-27 Centre National De La Recherche Scientifique A Dbait molecule against acquired resistance in the treatment of cancer

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
IT1054655B (it) * 1975-08-27 1981-11-30 Lepetit Spa Derivati condensati del l isochinolina
US4263304A (en) * 1978-06-05 1981-04-21 Sumitomo Chemical Company, Limited 7 H-indolo[2,3-c]isoquinolines
GB8828806D0 (en) 1988-12-09 1989-01-18 Beecham Group Plc Novel compounds
US5260316A (en) * 1991-07-30 1993-11-09 Ciba-Geigy Corporation Isoquinolyl substituted hydroxylamine derivatives
CZ281473B6 (cs) * 1991-08-29 1996-10-16 Vúfb, A.S. Deriváty 6-/X-(2-hydroxyethyl)aminoalkyl/-5,11 -dioxo-5,6-dihydro-11H-indeno/1,2-c/-isochinolinu a způsob jejich výroby
US5597831A (en) 1991-08-29 1997-01-28 Vufb A.S 6-[X-(2-hydroxyethyl) aminoalkyl]-5,11-dioxo-5,6-dihydro-11-H-indeno[1,2-c]isoquinolines and their use as antineoplastic agents
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
TW440562B (en) * 1994-05-20 2001-06-16 Taiho Pharmaceutical Co Ltd Condensed-indan derivative and pharmaceutically acceptable salts thereof
JP3643916B2 (ja) * 1995-11-17 2005-04-27 大鵬薬品工業株式会社 新規な縮合インデン誘導体又はその塩
US6250301B1 (en) 1997-08-28 2001-06-26 Hortal Harm B.V. Vaporizer for inhalation and method for extraction of active ingredients from a crude natural product or other matrix
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
WO1999011644A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) * 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6346536B1 (en) * 1997-09-03 2002-02-12 Guilford Pharmaceuticals Inc. Poly(ADP-ribose) polymerase inhibitors and method for treating neural or cardiovascular tissue damage using the same
AU9298798A (en) 1998-05-15 1999-12-06 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
JP2002515488A (ja) 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びｐａｒｐ活性の抑制方法
JP4580556B2 (ja) 1998-10-14 2010-11-17 パーデュー リサーチ ファウンデイション 抗腫瘍薬である新規インデノイソキノリン類
US6387902B1 (en) 1998-12-31 2002-05-14 Guilford Pharmaceuticals, Inc. Phenazine compounds, methods and pharmaceutical compositions for inhibiting PARP
US6201020B1 (en) 1998-12-31 2001-03-13 Guilford Pharmaceuticals, Inc. Ortho-diphenol compounds, methods and pharmaceutical compositions for inhibiting parp
ES2218110T3 (es) 1999-01-11 2004-11-16 Agouron Pharmaceuticals, Inc. Inhibidores triciclicos de poli(adp-ribosa)polimerasas.
US6346535B1 (en) * 1999-01-29 2002-02-12 American Cyanamid Company Fungicidal mixtures
US6531464B1 (en) * 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US6476048B1 (en) * 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6277990B1 (en) * 1999-12-07 2001-08-21 Inotek Corporation Substituted phenanthridinones and methods of use thereof
US6534651B2 (en) * 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
US6556035B2 (en) * 2001-04-26 2003-04-29 United Microelectronics Corp. Test key layout for detecting via-open failure
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
AU2004258801A1 (en) * 2003-02-28 2005-02-03 Inotek Pharmaceuticals Corporation Tetracyclic Benzamide Derivatives and methods of use thereof
US20050228007A1 (en) * 2004-02-26 2005-10-13 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
US20050261288A1 (en) * 2004-02-26 2005-11-24 Prakash Jagtap Tetracyclic lactam derivatives and uses thereof
JP2008503466A (ja) * 2004-06-16 2008-02-07 イノテック ファーマシューティカルズ コーポレイション 勃起不全または尿失禁を治療または予防する方法
MX2007010333A (es) * 2005-02-25 2007-11-06 Inotek Pharmaceuticals Corp Compuestos amino y carboxamido tetrac??clicos y m??todos para utilizar los mismos.
EP1850848A4 (en) * 2005-02-25 2008-02-20 Inotek Pharmaceuticals Corp SULFONAMIDE TETRACYCLIC COMPOUNDS AND METHODS OF USING THE SAME
AU2006219022A1 (en) * 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Isoqunoline Compounds and methods of use thereof
CA2620052A1 (en) * 2005-08-24 2007-03-01 Inotek Pharmaceuticals Corporation Indenoisoquinolinone analogs and methods of use thereof

Also Published As

Publication number Publication date
US20080262016A1 (en) 2008-10-23
EP1420785A4 (en) 2005-10-19
NO20040845L (no) 2004-04-01
DE60236170D1 (de) 2010-06-10
CA2457534A1 (en) 2003-03-13
NZ531218A (en) 2006-02-24
ATE465733T1 (de) 2010-05-15
WO2003020700A3 (en) 2004-02-12
US20030096833A1 (en) 2003-05-22
EP1420785B1 (en) 2010-04-28
WO2003020700A2 (en) 2003-03-13
US20030171392A1 (en) 2003-09-11
BR0212225A (pt) 2005-01-18
CN1575172A (zh) 2005-02-02
ZA200401376B (en) 2004-11-19
ECSP044997A (es) 2004-04-28
KR100922825B1 (ko) 2009-10-21
CN1880306A (zh) 2006-12-20
KR20040044486A (ko) 2004-05-28
EP1420785A2 (en) 2004-05-26
US6828319B2 (en) 2004-12-07
IL160437A0 (en) 2004-07-25
RU2300523C2 (ru) 2007-06-10
ES2345436T3 (es) 2010-09-23
EP2174659A1 (en) 2010-04-14
RU2004109141A (ru) 2005-03-27
JP2005502681A (ja) 2005-01-27
CN100503574C (zh) 2009-06-24
MXPA04001887A (es) 2005-03-07
AU2002329920B2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
CO5560543A2 (es) Derivados de indeno [1,2-c] isoquinolina y metodos para usar los mismos
FR20C1039I2 (fr) Derives de l'uk-2a
IL160051A0 (en) Ecteinascidin derivatives and pharmaceutical compositions containing the same
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
FI943749A0 (fi) Taksaanijohdannaisten fosfono-oksimetyylieetterit
AR028164A1 (es) Componentes de formula mejaradores de estabilidad, composiciones y metodo de lavado que los emplea.
EA200300050A1 (ru) Гликопептидфосфонатные производные
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
CO4910133A1 (es) Antagonistas de 5-h[1f]
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
ES2174298T3 (es) Derivados de aminotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
EE200200281A (et) Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks
BR0105563A (pt) Derivados e análogos de galantamina
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
CY1106376T1 (el) Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
CA2356985A1 (en) 5ht1 antagonists for antidepressant therapy
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
DK1331935T3 (da) Derivater af tryptamin og analoge forbindelser samt farmaceutiske formuleringer deraf
NO20002408D0 (no) 5-HT1F antagonister
AR004484A1 (es) Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen.
PT937708E (pt) Derivados de sulfonamidas
DK1373232T3 (da) Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner
DE60236623D1 (de) Amorphe substanz eines tricyclischen triazolobenzazepinderivats
DE60100045D1 (de) 1,2-Substituierte 2,3-dihydro-1H-5,9-dioxacyclohepta(f)inden-7-one und 7-substituierte Benzo(b)[1,4]dioxepin-3-one

Legal Events

Date Code Title Description
FC Application refused